Oncoinvent ASA (BRRGF) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Radspherin | Ovarian Cancer, Peritoneal Carcinomatosis | Phase II | Recruiting | A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery | Jul 10, 2024 | ― |
| Bemcentinib | Malignant Mesothelioma, Non-small Cell Lung Cancer, Acute Myeloid Leukemia, Glioblastoma, Myelodysplastic Syndromes, Metastatic Melanoma, Metastatic Pancreatic Cancer, Covid-19 | Phase I | Completed | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects | Jun 17, 2024 | ― |
| Carboplatin, Pembrolizumab, Pemetrexed, Bemcentinib | Carcinoma, Non-small-cell Lung | phase1AndPhase2 | Terminated | A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene | Jul 19, 2022 | ― |
| Tilvestamab | Ovarian Neoplasms | Phase I | Terminated | A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants | May 17, 2021 | ― |
| Soc, Bemcentinib | Covid-19 | Phase II | Completed | A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients | May 17, 2021 | ― |
| Bgb149 | Healthy Volunteers | earlyPhase1 | Completed | A First-time-in-human Study of BGB149 | Nov 23, 2018 | ― |
| Bemcentinib; Pembrolizumab | Triple Negative Breast Cancer, Inflammatory Breast Cancer Stage Iv | Phase II | Terminated | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | May 30, 2017 | ― |
| Bemcentinib; Pembrolizumab | Lung Cancer Metastatic, Nsclc Stage Iv, Adenocarcinoma Of Lung | Phase II | Completed | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | May 30, 2017 | ― |
| Cytarabine, Decitabine, Bemcentinib | Myelodysplastic Syndromes, Acute Myeloid Leukemia | phase1AndPhase2 | Completed | A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS | Apr 23, 2015 | ― |
| Erlotinib, Bemcentinib | Non-small Cell Lung Cancer | phase1AndPhase2 | Completed | A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer | Apr 09, 2015 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Radspherin | Phase II | Ovarian Cancer, Peritoneal Carcinomatosis | Recruiting | A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery | Jul 10, 2024 | ― |
| Bemcentinib | Phase I | Malignant Mesothelioma, Non-small Cell Lung Cancer, Acute Myeloid Leukemia, Glioblastoma, Myelodysplastic Syndromes, Metastatic Melanoma, Metastatic Pancreatic Cancer, Covid-19 | Completed | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects | Jun 17, 2024 | ― |
| Carboplatin, Pembrolizumab, Pemetrexed, Bemcentinib | phase1AndPhase2 | Carcinoma, Non-small-cell Lung | Terminated | A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene | Jul 19, 2022 | ― |
| Tilvestamab | Phase I | Ovarian Neoplasms | Terminated | A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants | May 17, 2021 | ― |
| Soc, Bemcentinib | Phase II | Covid-19 | Completed | A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients | May 17, 2021 | ― |
| Bgb149 | earlyPhase1 | Healthy Volunteers | Completed | A First-time-in-human Study of BGB149 | Nov 23, 2018 | ― |
| Bemcentinib; Pembrolizumab | Phase II | Triple Negative Breast Cancer, Inflammatory Breast Cancer Stage Iv | Terminated | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | May 30, 2017 | ― |
| Bemcentinib; Pembrolizumab | Phase II | Lung Cancer Metastatic, Nsclc Stage Iv, Adenocarcinoma Of Lung | Completed | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | May 30, 2017 | ― |
| Cytarabine, Decitabine, Bemcentinib | phase1AndPhase2 | Myelodysplastic Syndromes, Acute Myeloid Leukemia | Completed | A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS | Apr 23, 2015 | ― |
| Erlotinib, Bemcentinib | phase1AndPhase2 | Non-small Cell Lung Cancer | Completed | A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer | Apr 09, 2015 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Oncoinvent Asa (BRRGF) have in its pipeline
Oncoinvent ASA BRRGF is currently developing the following drugs: Radspherin, Bemcentinib, Carboplatin, Pembrolizumab, Pemetrexed, Bemcentinib, Tilvestamab, Soc, Bemcentinib, Bgb149, Bemcentinib; Pembrolizumab, Cytarabine, Decitabine, Bemcentinib, Erlotinib, Bemcentinib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.